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Introduction 
World-wide, injecting drug users ( IDU) represent a high risk group for bloodborne viral infections, 
including HIV 1, hepatitis B ( HBV ) 2 and hepatitis C ( HCV ) 3. Harm reduction strategies4 have 
been advocated in order to prevent spread of bloodborne viral infection and many believe that these 
approaches have contributed to a reduced incidence of HIV5,6. There is only limited evidence that 
needle exchange attendance is associated with a reduction in HCV and HBV infections7. A recent 
study of the incidence of HCV infection among IDU failed to find a reduction in those who 
attended for methadone maintenance therapy8. There is a concern that current approaches may not 
be adequate to reduce the occurrence of unsafe injecting practices to a sufficiently low level to 
ensure a low incidence of HCV in populations of IDU where the prevalence of HCV is already 
high3. It is possible for harm reduction programmes to appear effective by minimising new cases of 
HIV while having little impact on HCV. 
 
In Dublin harm reduction strategies have been in existence since 1989. These services have vastly 
expanded in the 1990’s. The number of official needle exchange centres in the city has grown from 
one to 12 since 1990, the number of community outreach workers has trebled in the same period 
and access to methadone treatment has improved with the addition of four new addiction treatment 
centres and 12 satellite clinics. Trinity Court is the largest and longest established treatment centre 
in Dublin. Referrals are accepted from all areas of the city. New attenders tend to present early in 
their injecting careers. Patients with a history of injecting are encouraged to agree to screening tests 
for HIV, HBV and HCV. We sought to measure the prevalences of these viral infections against the 
background of the expanding harm reduction programme. 
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Methods 
Since September 1992, data has been recorded on an ongoing basis on all new attenders who were 
IDU and tested for anti-HCV. When available, the results of screening tests for HBV and HIV were 
included. A doctor (BS), who was blind to the test results, obtained socio-demographic details and 
some drug use characteristics from the medical notes of the initial assessment interview. The 
variables chosen for inclusion were those found to be most frequently and reliably recorded in a 
pilot study prior to commencement of this project. Data was incomplete in only 28 cases (3.8%). 
We report here the results of the first five years of this data collection. 
 
Viral markers 
Prior to July 1993, the screening test for HCV was a second generation enzyme linked 
immunosorbant assay (EIA) for anti-HCV ( Ortho Diagnostics, Amersham, Buckinghamshire, 
England ). Subsequently, the third generation EIA was used. All positive results were confirmed 
with an additional EIA. A recombinant immunoblot assay was used in situations where the two EIA 
gave contradictory results. The screening test for HBV was an EIA for hepatitis B surface antigen. 
The initial screen for HIV was with two EIA tests for antibody to HIV. Positive tests were 
confirmed with the Western blot assay. 
 
Statistical methods 
Confidence intervals were calculated by using exact methods for proportions. Analytical techniques 
included Pearson’s chi squared test and Fisher’s exact test statistic to determine the significance of 
associations for categorical variables. For ordered categorical variables the Mantel-Haenszel chi-
squared test for linear trend was used. Odds ratios and their 95% confidence intervals were used to 
describe the relationship between subject characteristics and serology results. The Student’s t-test 
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was used for difference in the means of continuous variables except the Mann-Whitney U-test was 
performed when the distribution of a continuous variable was skewed. For HCV, multivariate 
analyses were performed using logistic regression and variables found to be significant on 
univariate analyses were entered into the regression equation9. 
 
Results 
 
Of 733 attenders, 453 were anti-HCV positive ( 61.8%, 95% confidence interval 58.3 - 65.3% ). 
Table 1 presents the relationship between anti-HCV and the socio-demographic and drug use 
variables. Older age, longer history of injecting, commencement of injecting prior to 1990 and daily 
drug expenditure of over Ir£65 were each significantly associated with increased risk. There was a 
tendency for unemployed attenders to be more likely to be anti-HCV positive (N.S.) and a similar 
tendency was observed in those who were in a sexual relationship with another IDU (N.S.). Figure 
1 depicts the association between duration of injecting and HCV status. Multivariate analysis 
indicated that only longer history of injecting and daily drug expenditure of over £65 were 
independently associated with increased risk of HCV. 
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Figure 1. Prevalences of anti-HCV, hepatitis B surface antigen and HIV in serial cohorts with 
increasing time since onset of injecting (1-4 months, 5-8 months, 9-12 months, 13-24 months, 25-60 
months and over 60 months, y-axis coordinate equates to the mean period since onset of injecting 
for each cohort): results from new attenders to the Trinity Court Drug Treatment Centre, Dublin, 
between September 1992 and September 1997. 
 
The prevalence of HBsAg was 1.0% ( 7/729, [95% confidence interval 0.3%-1.7%] ). The only 
independent variable significantly associated with increased risk of HBV was a history of injecting 
prior to 1990 ( see table 2, due to the small number testing positive, categories were compressed). 
Those testing positive for HBsAg had longer injecting histories but this was not significant ( 
medians, 45.0 months v 15.9 months, Mann Whitney U test, p=0.08) 
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Table 1. Distribution of general characteristics and injecting drug use behaviours of new attenders to the 
Trinity Court Drug Treatment Centre, Dublin, between September 1992 and September 1997, by anti-
HCV prevalence. Univariate and logistic regression analysis of associations. 
    Univariate analysis Multivariate analysis 
  Number 
(%) 
HCV 
prevalence 
Odds Ratio 
 (95% confidence 
interval) 
p value Odds Ratio 
(95% confidence 
interval) 
p value 
       
Total 733 61.8%     
       
Age, yrs       
 18 or less 126(17) 53.2% 1.0  1.0  
 19 to 21 249(34) 57.0% 1.17(0.74-1.84)  0.70(0.43-1.13) 0.14 
 22 to 24 160(22) 67.5% 1.83(1.10-3.05)  1.14(0.67-1.94) 0.64 
 25 or more 198(27) 68.7% 1.93(1.19-3.15) 0.001^ 0.80(0.44-1.33) 0.35 
       
Gender       
 Male 529(72) 61.4% 1.0    
 Female 204(28) 62.7% 1.06(0.76-1.47) 0.74*   
       
Employment       
 Working (or @ school) 75(10) 52.0% 1.0    
 Unemployed 658(90) 62.9% 1.57(0.97-2.53) 0.07*   
       
Current sexual relationshipa       
 No partner/ Non-injecting partner 493(70) 60.0% 1.0    
 Partner injects 214(30) 66.4% 1.31(0.93-1.86) 0.11*   
       
Time since onset of injecting, months.       
 1 to 4 109(15) 26.6% 1.0  1.0  
 5 to 8 108(15) 48.1% 2.56(1.40-4.71)  2.53(1.42-4.52) 0.002 
 9 to 12 99(14) 66.7% 5.52(2.92-10.49)  5.95(3.24-10.92) <0.001 
 13 to 24 183(25) 64.5% 5.01(2.88-8.74)  5.09(2.97-8.71) <0.001 
 25 to 60 158(22) 77.8% 9.69(5.30-17.84)  10.73(5.88-19.57) <0.001 
 > 60 76(10) 85.5% 16.30(7.14-38.02) <0.001^ 16.64(4.46-62.11) <0.001 
       
Principal drug injected       
 Heroin 544(74) 61.4% 1.0    
 Morphine sulphate(MST) 113(15) 62.8% 1.06(0.69-1.65)    
 Both heroin & MST 69(9) 65.2% 1.18(0.68-2.06)    
 Benzodiazepine b 7(1) 42.9% 0.47 0.68*   
       
Age 1st injected, yrs       
 18 or less 291(40) 62.9% 1.0    
 19 to 21 210(29) 59.5% 0.87(0.59-1.27)    
 22 to 24 142(19) 64.8% 1.09(0.70-1.69)    
 25 or more 90(12) 58.9% 0.85(0.51-1.41) 0.69*   
       
When injecting commenced       
 Pre 1990 81(11) 85.2% 1.0  1.0  
 Post 1990 652(89) 58.9% 0.25(0.13-0.47) <0.001* 0.85(0.26-2.80) 0.79 
       
Daily drug expediturec       
 Less than Ir£35 169(23) 57.4% 1.0  1.0  
 Ir£36 to Ir£65 314(43) 57.6% 1.01(0.68-1.50)  1.0(0.66-1.53) 0.99 
 More than Ir£65 248(34) 69.8% 1.71(1.12-2.63) 0.006* 1.79(1.14-2.79) 0.01 
       
       
Year of test        
 1993d 160(23) 67.6% 1.0    
 1994 177(24) 61.0% 0.75(0.47-1.19)    
 1995 152(21) 63.2% 0.82(0.50-1.33)    
 1996 118(16) 52.5% 0.53(0.32-0.88)    
 1997 116(16) 62.1% 0.78(0.46-1.32) 0.11^   
^ Mantel Haenszel chi-squared test for trend 
* Pearson chi-squared test 
a Status of partner unknown in 26 cases. 
b Numbers using benzodiazapines too low to allow valid calculation of 95% confidence interval for odds ratio.  
c Daily drug expenditure unknown in 2 cases. 
d Includes 20 patients tested between September 1992 and December 1992. 
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Table 2 General characteristics and injecting drug use behaviours of new attenders to the Trinity 
Court Drug Treatment Centre, Dublin, between September 1992 and September 1997, 
by HIV and hepatitis B surface antigen prevalences 
  HIV Hepatitis B sAg 
  Proportion testing 
positive (%) 
Fisher’s test   
- p value 
Proportion testing 
positive (%) 
Fisher’s test - p 
value 
       
Total 7/600a (1.2)  7/729b (1.0)  
       
Age       
 24 or less 1/438  (0.2)  4/533 (0.8)  
 25 or over 6/162  (3.7) 0.002 3/196 (1.5) 0.39 
        
Gender       
 Male 5/432  (1.2)  6/525  (1.1)  
 Female 2/168  (1.2) 1.0 1/204  (0.05) 0.68 
        
Employment       
 Unemployed  6/542 (1.1)  6/655 (0.9)  
 Working ( or @ school) 1/58 (1.7) 0.51 1/74 (1.4) 0.53 
        
Current sexual relationship       
 No partner/partner not injecting 4/402 (1.0)  5/491 (1.0)  
 Partner injecting 2/175 (1.1) 1.0 2/212 (0.9) 1.0 
        
Time since 1st injecting, years       
 Less than five years 3/538 (0.6)  5/654 (0.8)  
 Five years or more 4/62 (6.5) 0.003 2/75 (2.7) 0.16 
        
Principal drug injected       
 Heroin 7/457 (1.5)  5/541 (0.9)  
 Other 0/143 (0) 0.20 2/188 (1.1) 1.0 
        
Age 1st injected       
 24 or less 5/525 (1.0)  7/640 (1.1)  
 25 or more 2/75 (2.7) 0.22 0/89 (0) 1.0 
        
When injecting commenced       
 Pre 1990 4/64 (6.3)  3/80 (3.8)  
 Post 1990 3/536 (0.6) 0.003 4/649 (0.6) 0.03 
        
Daily drug expenditure       
 Ir£65 or less 3/405 (0.7)  3/481 (0.6)  
 More than Ir£65 4/194 (2.1) 0.22 4/246 (1.6) 0.23 
        
Year of testing       
 1992-1994 4/267 (1.5)  5/342 (1.5)  
 1995-1997 3/333 (0.9) 0.71 2/387 (0.5) 0.26 
a No HIV test was performed in 133 cases and the result was indeterminate in 2 cases. 
b No HBsAg test was conducted in 6 cases. 
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The prevalence of HIV was 1.2% (7/600, [95% confidence interval 0.3%-2.0%]). An 
injecting history of over five years, commencement of injecting prior to 1990 and age 
over 24 were each significantly associated with increased proportion testing positive for 
HIV ( see table 2 ). No test result was available in 133 cases and two results were 
indeterminate. Those reporting MST as their primary drug were underrepresented in the 
group tested for HIV ( Pearson’s x2 test, p=0.04 ). No other independent variable was 
associated with uptake of HIV testing.  
 
There was no significant association between any combination of the three viral 
markers. 
 
Discussion 
There are four possible areas of methodological concern in this study. Firstly, no data 
are presented on the reported frequency of unsafe injecting practices. Such practices are 
best examined via a standardised and detailed structured interview and possibly 
requiring an interviewer independent of treatment services10,11. Due to the long term 
nature of this ongoing study, there was no practical way of overcoming these obstacles 
and we therefore decided that no data on this area would be better than data of 
questionable reliability. Secondly, the daily drug expenditure was taken as a crude 
measure of daily drug use and injecting frequency. However, the ‘street’ price of heroin 
reduced by nearly 50% over the study period, falling to Ir£20 per ‘quarter gram’ in 
1996-97. A third possible source of concern could be the change in the HCV screening 
test from a second generation to a third generation EIA early in the study period. 
Although the enhanced specificity of the third generation test substantially increases the 
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positive predictive value of screening in very low prevalence populations such as blood 
donors, the change in positive predictive value in the high prevalence population 
studied here would be minimal12,13. Repeat examination of the data excluding those 
screened with the second generation test did not reveal any significant alteration in the 
reported findings on either univariate or multivariate analysis. Finally, there may be 
concern regarding possible selection bias in the HIV tested group as a substantial 
minority (18%) of the study group were not screened for HIV. Importantly, those not 
tested did not differ significantly in terms of any of the variables demonstrated to be 
associated with bloodborne infection. 
 
The variables significantly associated with increased risk of HCV are also those which 
are potentially associated with increased number of lifetime injecting episodes. Each 
injecting episode presents a possible scenario where the sharing of injecting equipment 
may occur14. Research conducted in Trinity Court in 1993 found that 56% of IDU had 
shared syringes in the preceding six months15. The prevalence of HCV in those who 
commenced injecting in this decade, and thereby had access to expanded harm 
reduction strategies, remains high at 58.9%. Although this proportion is significantly 
lower compared to those who began injecting earlier, multivariate analysis indicates 
that this finding is due to the confounding effect of shorter injecting history and could 
therefore not be used to support a conclusion that there has been any reduction in unsafe 
injecting practices. Figure 1 demonstrates the rapid acquisition of HCV after initiation 
into injecting. This supports the view expressed by Garfein and colleagues that those 
seeking to prevent spread of HCV among IDU have a very narrow window of 
opportunity in which to do so16. 
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The small proportion of IDU demonstrating current infectivity for HBV, indicates that 
the pool from which HBV infection can arise is very much smaller than the 
corresponding pool of HCV infection. Also the fact that most services dealing with IDU 
in Dublin, including prisons, have a policy of actively encouraging the uptake of HBV 
vaccination may also be contributing to its low prevalence. Screening for the antibody 
markers of HBV would have yielded valuable additional information about the 
proportion of IDU with previous exposure to this virus2. Unfortunately, such tests were 
not routinely performed.  
 
Johnson has reported a HIV prevalence of 14.8% among IDU attending a Dublin needle 
exchange in 199117. The prevalence detected among our study group is very much 
lower (1.2%). This reduction is striking but it must be noted that the group studied here 
are younger and injecting histories are shorter than the previously studied group. Our 
data demonstrates a sustained low prevalence of HIV among new attenders to our 
treatment service. In their review of cities with sustained low prevalence of HIV among 
IDU, Des Jarlais and colleagues have described three features which they considered 
important5. These are the adoption of harm reduction strategies early, utilisation of 
community outreach and ensuring access to sterile injecting equipment. Dublin has 
indeed embraced these approaches. Nevertheless, the observed reduction in prevalence 
of HIV infection in those who commenced injecting in this decade may simply reflect 
their shorter injecting history. Ongoing monitoring of HIV test results over the coming 
years may clarify this issue and will provide an area for further research. 
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Hepatitis C is associated with substantial morbidity and mortality18. Current harm 
reduction strategies appear ineffective in protecting IDU from this infection8,19. 
Proposed novel adaptations to these strategies will attempt to educate IDU ( or potential 
IDU ) during, or before, the narrow ‘window of opportunity’ and may in time prove 
beneficial16. In Europe, increasing numbers of drug misusers are being introduced to 
heroin through ‘chasing the dragon’ before possibly progressing on to injecting20. 
Education of this group regarding safe injecting and the risk of HCV should be 
considered. Overall, we believe that in Dublin, among IDU who commenced injecting 
in this decade, our data supports the view that hepatitis C will create a larger health 
burden than either hepatitis B or HIV/AIDS. Harm reduction approaches should adapt 
to this change in need. Hence, while the low prevalence of HIV must be welcomed, any 
decision by policy makers that funds could now be diverted away from harm reduction 
would be very premature. 
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Statistical methods 
 
Data analyses were with the statistical package for the social sciences (SPSS Inc., 
Chicago, USA) , version 7.51. For ordered categorical variables the Mantel-Haenszel 
chi-squared test for linear trend was used when data suggested a linear trend. The 
Mann-Whitney U-test was performed when the distribution of a continuous variable 
was skewed. For HCV, multivariate analyses were performed using logistic regression 
and variables found to be significant on univariate analyses were entered into the 
regression equation9. 
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